US protection ending in 2026: Immune system
As of the edition of 20 October 2026, 24 drugs have US protection that ends (or has ended) in 2026 in immune system; 12 of them have at least one company on route B because of it.
Sources: FDA Orange Book and Purple Book, other approval registers.
24 drugs
| Drug | US protection | Status | Holder | Target | Route B rows |
|---|---|---|---|---|---|
| Afamelanotide | Ended 2026 (exclusivity) | Marketed | Clinuvel | MC1R | 1 |
| Albiglutide | Ended 2026 (computed from the first US licence) | Marketed | GSK | GLP1R | 1 |
| Belinostat | Ended 2026 (patent) | Marketed | Acrotech Biopharma | 0 | |
| Conestat alfa | Ended 2026 (reference-product exclusivity) | Marketed | Pharming Americas BV | 0 | |
| Darunavir | Ends 2026 (patent) | Marketed | Johnson & Johnson | 0 | |
| Dasatinib anhydrous | Ended 2026 (exclusivity) | Marketed | ABL1, BLK, FGR | 12 | |
| Deflazacort | Ended 2026 (exclusivity) | Marketed | PTC Therapeutics | NR3C1 | 0 |
| Dulaglutide | Ended 2026 (computed from the first US licence) | Marketed | Eli Lilly | GLP1R | 0 |
| Elvitegravir | Ends 2026 (patent) | Marketed | Gilead Sciences | 0 | |
| Eribulin | Ended 2026 (exclusivity) | Marketed | Eisai | TUBB, TUBB1, TUBB2A | 9 |
| Escitalopram | Ended 2026 (exclusivity) | Marketed | AbbVie | SLC6A4 | 4 |
| Ivabradine | Ends 2026 (patent) | Marketed | Amgen | HCN4 | 3 |
| Lacosamide | Ended 2026 (exclusivity) | Marketed | UCB | SCN10A, SCN11A, SCN1A | 0 |
| Leuprolide | Ended 2026 (exclusivity) | Marketed | GNRHR | 1 | |
| Metreleptin | Ended 2026 (computed from the first US licence) | Marketed | Chiesi Farmaceutici | LEPR | 0 |
| Neisseria meningitidis factor h binding protein | Ends 2026 (reference-product exclusivity) | Marketed | Pfizer | 0 | |
| Onabotulinumtoxina | Ended 2026 (orphan exclusivity) | Marketed | AbbVie | SNAP25 | 0 |
| Pasireotide | Ends 2026 (patent) | Marketed | Recordati Rare Diseases | SSTR2, SSTR3, SSTR5 | 0 |
| Peginterferon beta-1a | Ended 2026 (computed from the first US licence) | Marketed | Biogen | IFNAR1, IFNAR2 | 0 |
| Ramucirumab | Ended 2026 (orphan exclusivity) | Marketed | Eli Lilly | KDR | 1 |
| Siltuximab | Ended 2026 (computed from the first US licence) | Marketed | Recordati Rare Diseases | IL6 | 2 |
| Sitagliptin | Ends 2026 (patent) | Marketed | Merck & Co. | DPP4 | 1 |
| Teduglutide | Ended 2026 (exclusivity) | Marketed | Takeda | GLP2R | 1 |
| Vedolizumab | Ended 2026 (computed from the first US licence) | Marketed | Takeda | ITGA4 | 1 |
Listed by name. A route B row is one company at one target; for a drug with one target that is the number of companies. US protection is the US only, and it is not the date generics or biosimilars can enter.
Which companies are on route B in 2026 in immune system
In the product12 of these 24 drugs have at least one company on route B. Which companies, and their scores, are in the product.
Get this list with the companies, scores and sources as a fileRequest access. Nothing is shown until you do.